期刊
ORAL DISEASES
卷 25, 期 -, 页码 49-63出版社
WILEY
DOI: 10.1111/odi.13041
关键词
biomarker; lymphoma; prediction; salivary glands; Sjogren's syndrome
资金
- American Academy of Oral Medicine
- European Association of Oral Medicine
- British Society for Oral Medicine
- Henry Schein Cares Foundation
- Colgate Palmolive
- Xerostom
- Afyx
- World Dental Education Foundation
- Unilever
- Oral Diseases
Objective To conduct a systematic review of studies exploring potential biomarkers for development, course, and efficacy of treatment of lymphomas in salivary glands of patients with Sjogren's syndrome. Material and Methods Eligible studies were identified through a comprehensive search of two databases, that is, PubMed and EMBASE. Quality of included articles was assessed with the Quality In Prognosis Studies (QUIPS) tool. The CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) was used to facilitate data extraction. Results Fifty-eight studies met the inclusion criteria. Only one study assessed the progression of lymphoma. Moderate risk of bias was detected in outcome measurement, study participation, and study confounding domains. Parotid gland enlargement, mixed monoclonal cryoglobulins, and low C4 levels represented strongest predictors of lymphoma development. The role of histological biomarkers, and specifically germinal centers, remains controversial. Clinical and methodological heterogeneity across studies precluded conduct of a meta-analysis. Conclusions Specific biomarkers in combination with clinical manifestations represent potential candidates for advancing precision medicine approaches to lymphoma prediction in patients with Sjogren's syndrome. Current focus has increasingly been on genetic and epigenetic markers as candidate predictors. Predictive accuracy of key biomarker candidates remains to be tested in well-designed prospectively followed Sjogren's syndrome cohorts.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据